St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
Primary Purpose
Atypical Depression
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
St. John's Wort extract
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Atypical Depression focused on measuring mild to moderate depression with atypical features according to DSM-IV
Eligibility Criteria
Main Inclusion Criteria:
- Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months
- Female and male Caucasians aged 18 to 70 years
- At least one of HAMD-28 scale items 22-26 scores >1
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00861978
First Posted
March 13, 2009
Last Updated
March 13, 2009
Sponsor
Cassella-med GmbH & Co. KG
1. Study Identification
Unique Protocol Identification Number
NCT00861978
Brief Title
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
Study Type
Interventional
2. Study Status
Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
December 2002 (undefined)
Primary Completion Date
November 2004 (Actual)
Study Completion Date
November 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cassella-med GmbH & Co. KG
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.
Detailed Description
The general picture of depression is still that of the traditionally called endogenous type, which is also the form that was characterized extensively in clinical trials. Atypical depression with reversed vegetative signs, such as hyperphagia or hypersomnia, is traditionalla neglected, demonstrated by the fact that in the most widely used depression scales, such as the Hamilton Depression Scale, melancholic symptoms have a specific weight, while, by contrast, reversed vegetative signs are not included. This etablishes a tendency to underestimate the severity of atypical depression.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atypical Depression
Keywords
mild to moderate depression with atypical features according to DSM-IV
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
201 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Placebo Comparator
Arm Title
2
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
St. John's Wort extract
Other Intervention Name(s)
Jarsin, LI 160
Intervention Description
Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria:
Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months
Female and male Caucasians aged 18 to 70 years
At least one of HAMD-28 scale items 22-26 scores >1
12. IPD Sharing Statement
Learn more about this trial
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
We'll reach out to this number within 24 hrs